Substitution of anti-androgens and tegafur-uracil combination therapy for castration-resistant prostate cancer: Results of a multi-center randomized phase II study

Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T and Ito H: Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol. 171:679–683. 2004. View Article : Google Scholar : PubMed/NCBI

Okihara K, Ukimura O, Kanemitsu N, Mizutani Y, Kawauchi A and Miki T: Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol. 14:128–132. 2007. View Article : Google Scholar : PubMed/NCBI

Suzuki H, Okihara K, Miyake H, et al: Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol. 180:921–927. 2008. View Article : Google Scholar

Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 350:1713–1721. 2004. View Article : Google Scholar : PubMed/NCBI

Nakajima T, Kinoshita T, Nashimoto A, et al: Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 94:1468–1476. 2007. View Article : Google Scholar

Kuriyama M, Takahashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol. 31:18–24. 2001. View Article : Google Scholar : PubMed/NCBI

Ichikawa W, Uetake H, Shirota Y, et al: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res. 9:786–791. 2003.

Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327. 2000.

Suda Y, Kuwashima Y, Tanaka Y, Uchida K and Akazawa S: Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluoropyrimidines. Anticancer Res. 19:805–810. 1999.

Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res. 4:2371–2376. 1998.

Ichikawa W, Uetake H, Shirota Y, et al: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer. 89:1486–1492. 2003. View Article : Google Scholar

Fukushima M, Morita M, Ikeda K and Nagayama S: Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med. 12:839–844. 2003.PubMed/NCBI

Hugosson J, Bergdahl S, Carlsson G, Frosing R, Norlen L and Gustavsson B: Effects of intravesical instillation of 5-fluorouracil and interferon in patients with recurrent superficial urinary bladder carcinoma. A clinical and pharmacodynamic study. Scand J Urol Nephrol. 31:343–347. 1997. View Article : Google Scholar

Nomura T, Nakagawa M, Fujita Y, Hanada T, Mimata H and Nomura Y: Clinical significance of thymidylate synthase expression in bladder cancer. Int J Urol. 9:368–376. 2002. View Article : Google Scholar : PubMed/NCBI

Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI

Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI

Naito S, Tsukamoto T, Koga H, et al: Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol. 38:365–372. 2008. View Article : Google Scholar : PubMed/NCBI

Longley DB, Ferguson PR, Boyer J, et al: Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin Cancer Res. 7:3533–3539. 2001.PubMed/NCBI

Isshi K, Sakuyama T, Gen T, et al: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol. 7:335–342. 2002. View Article : Google Scholar

Fujii R, Seshimo A and Kameoka S: Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol. 8:72–78. 2003. View Article : Google Scholar

Kawabata R, Oie S, Oka T, Takahashi M, Kanayama H and Itoh K: Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells. Int J Oncol. 38:665–676. 2011. View Article : Google Scholar

Scher HI, Halabi S, Tannock I, et al: Design and end-points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 26:1148–1159. 2008. View Article : Google Scholar